Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
0.01% RO7058584 · 1 trial · 2 indications
An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
IOP will be assessed by Goldman Applanation tonometry.
| Arm | Type | Description |
|---|---|---|
| 0.01% RO7058584 or Matching Placebo | EXPERIMENTAL | - |
| 0.1% RO7058584 or Matching Placebo | EXPERIMENTAL | - |
| 1% RO7058584 or Matching Placebo | EXPERIMENTAL | - |
| RO7058584 and Latanoprost 0.005% | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| 0.01% RO7058584 | DRUG | Once daily morning administration for 7 days |
| 0.1% RO7058584 | DRUG | Once daily morning administration for 7 days |
| 1% RO7058584 | DRUG | Once daily morning administration for 7 days |
| Matching Placebo | DRUG | Once daily morning administration for 7 days |
| Latanoprost 0.005% | DRUG | Once daily morning or evening dosing |
Inclusion Criteria: * 18 to 90 years of age inclusive, at the time of signing the informed consent form * Confirmed diagnosis of ocular hypertension (OHT) or primary open-angle glaucoma (POAG) in both eyes as determined by the investigator at screening * Treatment-naïve participants or participants...
0.01% RO7058584 is an investigational small molecule being developed by Roche for the treatment of glaucoma and open-angle glaucoma. It is administered as an eye drop and is currently in Phase 1 clinical development for these ophthalmic conditions.
0.01% RO7058584 is being developed by Roche Holding AG, which trades under the ticker RHHBY. The drug is an investigational small molecule in Phase 1 clinical development for the treatment of glaucoma and open-angle glaucoma.
0.01% RO7058584 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 study of the drug has been completed in patients with primary open angle glaucoma or ocular hypertension.
0.01% RO7058584 has one completed Phase 1 clinical trial, identified as NCT03293992. This study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of the drug following 7 days of eye drop instillation in patients with primary open angle glaucoma or ocular hypertension.
Yes, 0.01% RO7058584 is the same drug as RO7058584. The 0.01% refers to the concentration of the drug in the eye drop formulation. The drug is being developed by Roche for the treatment of glaucoma and open-angle glaucoma.